2A-BETA,3,4,5A-ALPHA,6,7,8,8A-BETA,8B-DECAHYDRO-2-BETA-METHOXY-6,6,8B-BETA-TRIMETHYL-3-OXO-2H-NAPHTHO-[1,8-BC]-FURAN
Compound with spectra: 1 NMR
![2A-BETA,3,4,5A-ALPHA,6,7,8,8A-BETA,8B-DECAHYDRO-2-BETA-METHOXY-6,6,8B-BETA-TRIMETHYL-3-OXO-2H-NAPHTHO-[1,8-BC]-FURAN](/api/compound/LuzaNVV48X4.png?ph=true&h=300&w=458 "2A-BETA,3,4,5A-ALPHA,6,7,8,8A-BETA,8B-DECAHYDRO-2-BETA-METHOXY-6,6,8B-BETA-TRIMETHYL-3-OXO-2H-NAPHTHO-[1,8-BC]-FURAN")
| SpectraBase Compound ID | LuzaNVV48X4 |
|---|---|
| InChI | InChI=1S/C15H24O3/c1-14(2)8-7-11-15(3)10(14)6-5-9(16)12(15)13(17-4)18-11/h10-13H,5-8H2,1-4H3/t10-,11-,12-,13+,15+/m0/s1 |
| InChIKey | ZTNBOHZLWACMQB-XOBFJNJYSA-N |
| Mol Weight | 252.35 g/mol |
| Molecular Formula | C15H24O3 |
| Exact Mass | 252.172545 g/mol |
| Enantiomer InChIKey | ZTNBOHZLWACMQB-NTASLKFISA-N |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | CDCl3 |
(-)-2.beta.-Methoxy-2a.beta.,3,4,5,5a.alpha.,6,7,8,8a.beta.,8b.beta.-decahydro-6,6,8b.beta.-trimethyl-2H-naphtho[1,8-bc]furan-5-one
3-[BETA],11-DIHYDROXY-DRIM-8(12)-EN-3-O-[BETA]-D-GLUCOPYRANOSIDE
(1-S,5-R,6-S,7-S,8-S,10-R,11-R)-6-HYDROXY-4-OXOPSEUDOGUAI--12,8-OLIDE
ENT-3-BETA-ACETOXY-PIMARA-8(14),15-DIENE
(12R,13S)-11,12-EPOXY-12-METHOXY-14,15-DINORLABD-13-ONE
(12S,13R)-11,12-EPOXY-12-METHOXY-14,15-DINORLABD-13-ONE
2,2,4,4-tetramethyl-3-pentyl trans-decahydro-6.beta.-[tert-butyldimethylsilyl)oxy]-5,5,8a.beta.-trimethyl-2-methylene-1.xi.-naphthalenecarboxylate
CERIOPSIN-C;1-BETA,15(S)-ISOPIMAR-7-ENE-1,15,16-TRIOL
3.beta.,21.alpha.-Diacetoxy-26-nor-8,14-seco-gamma-ser-14(27)-en-8-one
(2a.beta.,5a.alpha.,8a.beta.,8b.beta.)-2a,3,5a,6,7,8,8a,8b-octahydro-3-oxo-6,6,8b-trimethyl-2H-naphtho[1,8-bc]furan-2-one
| Title | Journal or Book | Year |
|---|---|---|
| Synthetic and structural studies of key intermediates toward forskolin and/or erigerol. Relative stereochemistry, conformational preferences and stereoselectivity control | J. Chem. Soc., Perkin Trans. 1 | 1993 |